Chinese english Germany Korea

7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester

化学構造式
1190897-27-8
CAS番号.
1190897-27-8
化学名:
别名:
英語名:
7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester
英語别名:
tert-butyl 3-oxo-5,6,8,9-tetrahydro-2H-pyridazino[3,4-d]azepine-7-carboxylate;tert-Butyl 3-oxo-2,3,5,6,8,9-hexahydro-7H-pyridazino[3,4-d]azepine-7-carboxylate;7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester
CBNumber:
CB59938046
化学式:
C13H19N3O3
分子量:
265.31
MOL File:
1190897-27-8.mol

7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester 物理性質

比重(密度) :
1.26±0.1 g/cm3(Predicted)
酸解離定数(Pka):
10.78±0.20(Predicted)

安全性情報

7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester 価格

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入

7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester 化学特性,用途語,生産方法

7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester 上流と下流の製品情報

原材料

準備製品

7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester 生産企業

Global( 4)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Suzhou ARTK Medchem Co., Ltd. 		+86-512-68323967 +86-18015559028
 sales1@artkmedchem.com China 39009 58
Bide Pharmatech Ltd. 400-1647117 15221909166
 product02@bidepharm.com China 63720 58
Shanghai Jieshikai Biotechnology Co. , Ltd. 021-57520305 13795461237
 zhuruyan@jskchem.com China 49242 58
PharmaBlock Sciences (Nanjing), Inc. 4000255188
 sun_dan@PharmaBlock.com China 7268 58
  • 1190897-27-8
  • 7H-Pyridazino[3,4-d]azepine-7-carboxylic acid, 2,3,5,6,8,9-hexahydro-3-oxo-, 1,1-dimethylethyl ester
  • tert-Butyl 3-oxo-2,3,5,6,8,9-hexahydro-7H-pyridazino[3,4-d]azepine-7-carboxylate
  • tert-butyl 3-oxo-5,6,8,9-tetrahydro-2H-pyridazino[3,4-d]azepine-7-carboxylate
Copyright 2017 © ChemicalBook. All rights reserved